| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| ln Vivo |
(Rac)-Modipafant (UK-74505) (10 mg/kg; PO; twice daily until day 10) stops serious dengue infection [3]. With an IC50 of 26.3 and 1.12 nM following 0.25 and 60 minutes of preincubation, respectively, (Rac)-Modipafant exhibits a highly selective, time-dependent suppression of PAF-induced aggregation of washed rabbit platelets [4]. (Rac)-Modipafant reduces zymosan-induced joint hyperalgesia in a dose-dependent manner (5–20 mg/kg; oral) [5].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: 8 to 10 weeks old balb/c (Bagg ALBino) mouse (DEN-2 strain infection) [3]
Doses: 10 mg/kg Route of Administration: Po; twice (two times) daily (starting on day 0, 3, 5 or 7 ) until day 10. Experimental Results: The mortality rate associated with DEN-2 infection was diminished by approximately 50%. Animal/Disease Models: Male BALB/C (8 to 10 weeks old) wild-type mice [5] Doses: 5, 10 and 20 mg/kg Route of Administration: Oral Experimental Results: Dose-dependent inhibition of zymosan-induced joint pain allergy. |
| References |
|
| Additional Infomation |
See also: Modipafant (annotation moved to).
|
| Molecular Formula |
C34H29CLN6O3
|
|---|---|
| Molecular Weight |
605.095
|
| Exact Mass |
604.199
|
| CAS # |
122956-68-7
|
| Related CAS # |
Modipafant;122957-06-6
|
| PubChem CID |
129796
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.34g/cm3
|
| Index of Refraction |
1.681
|
| LogP |
7.329
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
44
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ODRYSCQFUGFOSU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)
|
| Chemical Name |
ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate
|
| Synonyms |
UK 74505; UK-74505; Modipafant racemate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~82.63 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6526 mL | 8.2631 mL | 16.5262 mL | |
| 5 mM | 0.3305 mL | 1.6526 mL | 3.3052 mL | |
| 10 mM | 0.1653 mL | 0.8263 mL | 1.6526 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
